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ABSTRACT
*HQHWKHUDS\LVDQDWWUDFWLYHDSSURDFKIRUKHSDWRFHOOXODUFDUFLQRPD+&&SDWLHQWV
1HYHUWKHOHVVHI¿FLHQWWUDQVJHQHGHOLYHU\UHPDLQVDFKDOOHQJH,QWKLVVWXG\ZH
H[SORUHGDQHZWDUJHWHGV\VWHPEDVHGRQKXPDQXPELOLFDOFRUGGHULYHGPHVHQFK\PDO
VWHPFHOOV+806&VZKLFKZHUHHQJLQHHUHGWRGHOLYHUDGHQRYLUXVWRWXPRUVLWHVDQG
WRUHSOLFDWHDQGDVVHPEOHLQWRQHZDGHQRYLUXVDJDLQVW+&&2XUUHVXOWVVKRZHGWKDW
+806&VLQIHFWHGE\$GK7(57S,/IROORZHGE\/HQWL5($LQIHFWLRQFRXOGVSHFL¿FDOO\
PLJUDWHWR+HS*WXPRUFHOOVDQGVXSSRUWDGHQRYLUDOUHSOLFDWLRQLQYLWURDQGLQYLYR
KDIWHU/HQWL5($LQIHFWLRQ$GK7(57S,/VSHFL¿FDOO\LQKLELWHG+HS*FHOOVJURZWK
DQGWKLVLQKLELWRU\HIIHFWZDVHQKDQFHGE\ORZGRVHVRIÀXRURXUDFLO)XEHFDXVH
WKHH[SUHVVLRQOHYHOVRIFR[VDFNLHDGHQRYLUXVUHFHSWRU&$5DQGLQWHJULQĮǌǃRQ
WXPRUFHOOVZHUHVLJQL¿FDQWO\LQFUHDVHGFDXVLQJKLJKHUYLUDOXSWDNH&RPSDUHGZLWK
WKHQRWUHDWPHQWJURXSV$GK7(57S,/DQG/HQWL5($FRORDGHG+806&VH[KLELWHG
VLJQL¿FDQWDQWLWXPRUDFWLYLW\LQYLYRSDUWLFXODUO\LQFRPELQDWLRQZLWKORZGRVHVRI
)X,QVXPPDU\WKLVVWXG\SURYLGHVDSURPLVLQJWDUJHWHGJHQHWKHUDSHXWLFVWUDWHJ\
GHSHQGHQWRQWKHWXPRUWURSLVPRI+806&VWRLPSURYHWKHRXWFRPHRIYLURWKHUDS\
IRUWXPRUSDWLHQWVHVSHFLDOO\WKRVHZLWKPHWDVWDWLFGLVHDVHV
INTRODUCTION
Gene therapy is an attractive and promising 
approach to cancer treatment. Currently, adenoviral 
vectors have been employed for gene therapy due to 
their low pathogenicity, high titer and lack of integration 
LQWR WKH KRVW FHOOV¶ JHQRPHV 7KH ³¿UVW JHQHUDWLRQ´
YHFWRUV UHSOLFDWLRQGH¿FLHQW YHFWRUV EDVHG RQ KXPDQ
adenovirus serotypes 5 (Ad5), in which the E1 and E3 
regions of the genome are deleted, are the most widely 
used [1]. Clinical studies have shown that administration 
RIUHSOLFDWLRQGH¿FLHQWDGHQRYLUDOYHFWRUVLQWUDWXPRUDOO\
intraperitoneally and intravesically is a safe, feasible and 
effective antitumor strategy against many types of cancers 
[2]. Nevertheless, the major concerns over the use of such 
YHFWRUVOLHLQWKHLQHI¿FLHQWYLUDOGHOLYHU\WRWKHPHWDVWDWLF
tumor sites due to the fact that the metastatic tumors 
are often smaller and directly inaccessible. Moreover, 
systemic administration of high doses of adenovirus is 
associated with systemic toxicity and rapid elimination 
of the virus by the immune system before reaching the 
tumor [3]. Thus, it is absolutely critical to develop an 
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HI¿FLHQW DQG WDUJHWHG GHOLYHU\ V\VWHP IRU LQWUDYHQRXV
administration of adenoviral vectors to improve the 
clinical outcome of patients with recurrent and metastatic 
lesions.
Mesenchymal stem cells (MSCs) have been shown 
to migrate toward malignant tumors and track microscopic 
metastasis when administered by intravenous injection in 
vivo [4, 5]. Further, engineered MSCs have been indicated 
as a potential vehicle to deliver anticancer agents to 
primary and metastatic tumors [6–8]. At present, scientists 
have successfully taken advantage of MSCs to deliver 
antitumor agents, including cytokines [5], interferons [9], 
pro-drugs [10] and conditionally replicating virus [11]. 
Human umbilical cord’s Wharton’s jelly (WJ)-derived 
PHVHQFK\PDOVWHPFHOOV+806&VZHUH¿UVWGHVFULEHG
by McElreavey et al [12]. HUMSCs share common 
characteristics of MSCs, such as immunosuppression, 
H[SUHVVLRQ RI D SKHQRW\SLFDOO\ GH¿QHG VHW RI VXUIDFH
markers (CD90, CD105 and CD73), multi-differentiation 
potential to the osteogenic, adipogenic and chondrogenic 
lineages [13], and ability to accumulate at sites of 
WLVVXHGDPDJHLQÀDPPDWLRQDQGWXPRUVLQYLYR>@,Q
addition, HUMSCs are advantageous in term of rapid 
cell expansion, yield, ease of procedure, lack of ethical 
problems and are suitability for genetic engineering with 
viral vectors [14]. These characteristics make HUMSCs to 
be a promising platform for targeted delivery of anticancer 
agents for a variety of cancers.
To enhance the transfer of adenovirus to tumor cells, 
we engineered the HUMSCs to produce an adenovirus 
HQFRGLQJ DQWLWXPRU DJHQWV 7KH UHSOLFDWLRQGH¿FLHQW
adenoviral vectors based on Ad-5 can be propagated 
in complementing human cell lines that provide the 
E1 proteins [15]. Therefore, if E1A proteins, which 
are essential for the replication of the adenovirus, were 
supplied in HUMSCs, the HUMSCs would permit 
UHSOLFDWLRQGH¿FLHQW DGHQRYLUXVHV WR EH UHSOLFDWHG DQG
SDFNDJHG>@7RWKLVHQG+806&VZHUH¿UVWLQIHFWHGE\
UHSOLFDWLRQGH¿FLHQWDGHQRYLUXVHVKDUERULQJWKHDQWLWXPRU
JHQHDQGWKHQPRGL¿HGE\OHQWLYLUXVHVH[SUHVVLQJ($
proteins. The engineered HUMSCs not only delivered 
adenoviral vehicles to tumor or metastatic tumor sites but 
also supported the adenoviral replication. Ultimately, the 
UHFRPELQDQWDGHQRYLUXVZDVDPSOL¿HGDQGSDFNDJHGDQG
released, allowing the infection of the surrounding tumor 
cells to express the target therapeutic proteins.
,Q WKLV VWXG\ PHODQRPD GLIIHUHQWLDWLRQ DVVRFLDWHG
JHQHLQWHUOHXNLQ PGD,/ ZDV FKRVHQ DV WKH
target therapeutic protein carried by the adenoviral vectors. 
,/DPHPEHURIWKH,/IDPLO\FDQVHOHFWLYHO\LQGXFH
apoptosis in a variety of cancer cells without affecting the 
normal cells in vitro [17, 18], in vivo [17, 19, 20], and in 
DSKDVH,FOLQLFDO WULDO >@0RUHRYHUXQWUDQVIHFWHG
neighboring cancer cells can be killed by the bystander 
HIIHFWRIPGD,/>@7RHQKDQFHWKHVHFRQGDU\
DQWLWXPRU VSHFL¿FLW\ WKH H[SUHVVLRQ RI ,/ LV GULYHQ
by the human telomerase reverse transcriptase (hTERT) 
promoter, which is highly active in over 85% of human 
cancer cells but inactive in most somatic cells. The hTERT 
promoter has shown great potential in regulating the cell-
VSHFL¿FH[SUHVVLRQRIH[RJHQRXVWKHUDSHXWLFJHQHVLQWXPRU
FHOOVZLWKRXWLQÀXHQFLQJWKHQRUPDOWLVVXHV>@
:H HYDOXDWHG WKH HI¿FDF\ RI WKLV GXDO WDUJHWLQJ
therapeutic system in vitro and in vivo in hepatocarcinoma 
models. Our results showed that adenovirus-loaded 
HUMSC.lentiR.E1A could support adenoviral replication 
and viral particle release to infect the tumor cells. 
Moreover, virus-loaded HUMSCs were still capable 
of migrating to hepatocellular carcinoma. The tumor 
suppressive effect of this dual targeted therapeutic system 
was also observed in vitro and in vivo. Furthermore, 
we investigated the synergistic antitumor effect of this 
dual targeted therapeutic system in combination with 
ÀXRURXUDFLO)X
RESULTS
&XOWXUHDQGLGHQWL¿FDWLRQRI+806&V
The HUMSCs, obtained from the WJ of human 
umbilical cord with informed consents, had a typical 
VSLQGOHVKDSHDQGUHVHPEOHG¿EUREODVWVFRQVLVWHQWZLWK
the morphology reported by others [12, 27]. Although 
D VSHFL¿F DQWLJHQ SUR¿OH RI +806&V KDV QRW EHHQ
GH¿QHG IRU HDFK LVRODWLRQ DQG FXOWXUH ZH YHUL¿HG E\
ÀRZF\WRPHWU\WKDWWKHLVRODWHGFHOOVZHUHSRVLWLYHIRUWKH
mesenchymal markers CD73, CD90 and CD105 (Figure 
1A) and negative for typical hematopoietic antigens CD34, 
CD45 and CD19 (Figure 1B) as previously described 
[13]. Moreover, the HUMSCs were able to undergo 
adipogenesis (Figure 1C) and osteogenesis (Figure 1D) 
XQGHUVSHFL¿FGLIIHUHQWLDWLQJFRQGLWLRQVLQYLWUR
7KHVSHFL¿FDFWLYLW\RIK7(57SURPRWHUDQGWKH
WUDQVIHFWLRQHI¿FLHQF\RIYLUXV
:H VXFFHVVIXOO\ FORQHG WKH VSHFL¿F K7(57
SURPRWHU VHTXHQFH ES WKH ,/ JHQH DQG WKH
($JHQHZKRVHQXFOHRWLGHVHTXHQFHVZHUHYHUL¿HGE\
'1$VHTXHQFLQJ7RH[DPLQHWKHVSHFL¿FWUDQVFULSWLRQDO
activity of the hTERT promoter, we performed a dual-
OXFLIHUDVHUHSRUWHUDVVD\XVLQJDS*/K7(57SUHSRUWHU
SODVPLG)LJXUH(/XFLIHUDVHDFWLYLW\LQS*/K7(57S
was expressed as a percentage of the positive control 
SODVPLGS*/&RQWUROGULYHQE\ WKH69HQKDQFHU
SURPRWHU$S*/%DVLFSODVPLGZLWKRXWWKHHQKDQFHU
promoter sequence was used for negative control. HepG2, 
BJAB and K562 cells exhibited high transcriptional 
activity, whose values were 49.73±5.49%, 64.52±5.53%, 
and 134.59±16.25% of the positive control activity, 
UHVSHFWLYHO\ )LJXUH ) ,Q FRQWUDVW QHLWKHU QRUPDO
human embryonic lung MRC-5 cells nor HUMSCs 
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)LJXUH,GHQWL¿FDWLRQRI+806&VWKHVSHFL¿FDFWLYLW\RIK7(57SURPRWHUDQGDGHQRYLUDOWUDQVIHFWLRQHI¿FLHQF\ 
$ Representative histogram overlays of FACS analysis showed the isolated HUMSCs were positive for CD73, CD90 and CD105. 
% Representative histogram overlays of FACS analysis showed the negative antigens of HUMSCs: CD34, CD19 and CD45. & The 
representative microscope image showed differentiation of HUMSCs into the adipogenic lineages in vitro. Cells were stained with Oil-
red O. ' The representative microscope image showed differentiation of HUMSCs into the osteogenic lineages in vitro. Cells were 
VWDLQHGZLWK$OL]DULQUHG&'VFDOHEDU ȝP( The schematic representation displayed the vectors involved in the study. ) The 
VSHFL¿FWUDQVFULSWLRQDODFWLYLW\RIK7(57SURPRWHULQGLIIHUHQWFHOOOLQHVZDVGHWHFWHGE\DGXDOOXFLIHUDVHUHSRUWHUDVVD\* Adenoviral 
WUDQVIHFWLRQHI¿FLHQFLHVDWGLIIHUHQW02,DIWHUKRXUVLQWKUHHLQGHSHQGHQW+806&VDPSOHVZHUHHYDOXDWHGE\)$&6DQGH[SUHVVHGDV
mean ± SD. +7KHUHSUHVHQWDWLYHLPDJHVGHSLFWHGWKHWUDQVIHFWLRQHI¿FLHQF\RI06&VZLWK02,$G7UDFNKRXUVDIWHULQIHFWLRQ
+806&VFDUU\LQJ*)3ZHUHREVHUYHGXQGHUÀXRUHVFHQW¿HOGOHIWSDQHODQGEULJKW¿HOGULJKWSDQHOVFDOHEDU ȝP
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showed evident transcriptional activity, with values of 
1.73±0.71% and 2.99±1.07% of the positive control 
DFWLYLW\ UHVSHFWLYHO\7KHVH¿QGLQJVVXJJHVWHG WKDW WKH
K7(57SURPRWHUZHFORQHGKDGDVSHFL¿FWUDQVFULSWLRQDO
activity in cancer cells but not in normal cells.
1H[W WKH OHQWLYLUDO H[SUHVVLRQ YHFWRUV S/HQWL5
E1A and the adenoviral expression vectors pAd-hTERTp-
,/ZHUHVXFFHVVIXOO\GHYHORSHG7KH02,RIOHQWLYLUXV
RI+806&VZDVVHWDW02,DVSUHYLRXVO\GHVFULEHG
>@:HGHWHFWHGWKHDGHQRYLUDOLQIHFWLRQHI¿FLHQF\RI
HUMSCs using AdTrack at 48 h after infection. Flow 
F\WRPHWU\ UHYHDOHG WKH HI¿FLHQFLHV ZHUH 
DQGDW02,DQG
respectively (Figure 1G). Based on these results, for 
WKHIROORZLQJH[SHULPHQWVZHFKRVH02,DWZKLFK
+806&VFRXOGEHWUDQVIHFWHGHI¿FLHQWO\ZLWKRXWDIIHFWLQJ
their growth (Figure 1H).
5HSOLFDWLRQGH¿FLHQWDGHQRYLUXVHVDPSOL¿HG
LQ+806&/HQWL5($DQGZHUHHYHQWXDOO\
UHOHDVHGIURPWKHFHOOV
To directly verify whether the replication-
GH¿FLHQW DGHQRYLUXV FDQ EH DPSOL¿HG LQ +806&
/HQWL5($ ZH GHWHFWHG WKH FRQFHQWUDWLRQV RI WKH
hexon gene, a late adenoviral gene, intracellularly and 
in the supernatant of virus-loaded HUMSCs at the 
LQGLFDWHG WLPH SRLQWV DIWHU$G7UDFN DQG/HQWL5($
co-infection. Hexon gene expression was measured 
by quantitative PCR to determine the copy number of 
DGHQRYLUDO'1$7KHVWDUWRI/HQWL5($LQIHFWLRQZDV
set as 0 h. As the expression of E1A increased gradually 
(Figure 2A), the total concentration of adenoviral DNA 
(intracellularly and in the supernatant) in the HUMSC.
/HQWL5($JURXSLQFUHDVHGUDSLGO\DIWHUKZKHUHDV
the adenoviral DNA was not detected in the control 
JURXSRI+806&/HQWL5)LJXUH%,QSDUWLFXODUWKH
intracellular concentration of adenoviral DNA increased 
synchronously and sharply between 36 and 48 h after 
infection, and lasted until 72 h, while the supernatant 
concentration of viral DNA increased gradually and 
UHDFKHG SHDN OHYHOV DW  K LQ WKH +806&/HQWL5
E1A group (Figure 2C). Further, electron microscopy 
YHUL¿HGWKHSUHVHQFHRILQWUDFHOOXODUYLUDOSDUWLFOHVLQ
the HUMSCs 48 h after the infection (Figure 2D). These 
results indicated that viral DNA was synthesized and 
assembled into new viral particles in the HUMSCs co-
LQIHFWHGE\$G7UDFNDQG/HQWL5($)ORZF\WRPHWU\
ZDVXVHGWRGHWHFWWKHLQIHFWLRQHI¿FLHQF\RI+HS*
h after co-culture of virus-loaded HUMSCs and HepG2. 
)LJXUH5HSOLFDWLRQGH¿FLHQWDGHQRYLUXVHVDPSOL¿HGLQ+806&/HQWL5($DQGZHUHHYHQWXDOO\UHOHDVHGIURPWKH
FHOOV $7KHP51$H[SUHVVLRQOHYHORI($DWLQGLFDWLQJWLPHSRLQWVDIWHU/HQWL5($LQIHFWLRQ% The total concentration (intracellularly 
and in the supernatant) of viral DNA was measured at different time points in in three independent samples of HUMSC sequentially infected 
E\$G7UDFNDQG/HQWL5($/HQWL57KHVWDUWRI/HQWL5($LQIHFWLRQZDVVHWDVK& The intracellular and supernatant concentration 
of viral DNA were detected at different time points respectively. ' Electron micrographs show viral particles in the HUMSC sequentially 
LQIHFWHGE\$G7UDFNDQG/HQWL5($$GHQRYLUXVSDUWLFOHVZHUHVKRZQE\WKHEODFNDUURZ/HIWSDQHODWORZPDJQL¿FDWLRQ5LJKWSDQHO
DWKLJKPDJQL¿FDWLRQ(7KHLQIHFWLRQHI¿FLHQF\RI+HS*ZDVGHWHFWHGE\)$&6KDIWHUFRFXOWXUHRIYLUXVORDGHG$G7UDFNDQG
/HQWL5($+806&VDQG+HS*ZLWKGLIIHUHQWUDWLRVLQWKUHHLQGHSHQGHQWVDPSOHV
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7KHLQIHFWLRQHI¿FLHQFLHVZHUH
55.5±3.5% and 72.4±3.9% at HUMSCs: HepG2 ratio of 
1:20, 1:10, 1:4 and 1:1, respectively (Figure 2E). These 
observations indicated that the released viral particles 
have the ability to infect cells.
0LJUDWLRQFDSDFLW\RIYLUXVORDGHG+806&VWR
KHSDWRFDUFLQRPDLQYLWURDQGLQYLYR
+806&VDQGPRGL¿HG+806&VZHUHSUHYLRXVO\
shown to have a homing predisposition to tumor cells in 
vitro and to the tumor site in hepatocarcinoma models, 
and their migration capacity presents a concentration–
dependent pattern [28]. However, in this study, the 
virus-loaded HUMSCs would be lysed after 36 h of 
/HQWL5($ LQIHFWLRQ EHFDXVH DGHQRYLUXV UHSOLFDWLRQ
and packaging was activated by the expression of 
E1A, as described in Figure 2B. To test the migration 
capacity of virus-loaded HUMSCs within 36 h after 
infection, in vitro migration assays using Transwell 
SODWHV ZHUH SHUIRUPHG 8QPRGL¿HG +806&V ZHUH
XVHG DV D SRVLWLYH FRQWURO :H FRQ¿UPHG WKDW YLUXV
loaded HUMSCs migrated towards HepG2 cultures in 
DVLPLODUSDWWHUQDVXQPRGL¿HG+806&VZLWKLQK
after infection (Figure 3A, 3B). These results indicated 
that human hepatocellular carcinoma HepG2 cells were 
capable of stimulating the migration of HUMSCs and 
that the migration ability of HUMSCs was not affected 
by adenoviral and lentiviral co-infection.
Next, to investigate the homing capability of virus-
loaded HUMSCs in vivo, we designed an adenoviral 
YHFWRUS$G/XFKDUERULQJD¿UHÀ\OXFLIHUDVHUHSRUWHU
JHQH)LJXUH(5HSUHVHQWDWLYH%LROXPLQHVFHQW,PDJLQJ
%/,DQDO\VLVLQYLYRUHYHDOHGWKDWGD\DIWHULQMHFWLRQ
)LJXUH 0LJUDWLRQ FDSDFLW\ RI YLUXVORDGHG+806&V WR KHSDWRFDUFLQRPD LQ YLWUR DQG LQ YLYR $ Representative 
photographs showed the migrated HUMSCs stained with crystal violet in vitro migration assays using Transwell plates. % The numbers of 
migrated HUMSCs in three independent samples were expressed as mean ± SD. &7KHKRPLQJFDSDELOLW\RI+806&/HQWL5$G/XFWR
tumor sites was monitored by bioluminescence imaging using Xenogen imaging system at indicated times after tail vein injection. ' The 
KRPLQJFDSDELOLW\RIYLUXVORDGHG+806&/HQWL5($$G/XFWRWXPRUVLWHVZDVPRQLWRUHGLQYLYR
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RI +806&/HQWL5$G/XF LQWHQVH ¿UHÀ\ OXFLIHUDVH
signal was detected at the tumors site. 2 days after the 
injection, the signal further increased, and it lasted until 
GD\V)LJXUH&,QWKH+806&/HQWL5($$G/XF
injection group, the intense imaging signal could also be 
detected at the tumor site 1 day after the injection, and 
disappeared after 4 days. The signal was discovered 
once again 7 days after the injection, indicating that the 
UHFRPELQDQW $G/XF ZDV DPSOL¿HG DQG SDFNDJHG LQ
+806&/HQWL5($ DQG WKHQ UHOHDVHG WR LQIHFW WKH
surrounding tumor cells (Figure 3D).
6SHFL¿FWXPRUVXSSUHVVLQJHIIHFWVRI
$GK7(57S,/DQGORZGRVH)XFRXOG
HQKDQFHJURZWKLQKLELWLRQRI+HS*FHOOV
7R HYDOXDWH WKH VSHFL¿F LQKLELWRU\ HIIHFWV RI
$GK7(57S,/ LQ WXPRU FHOOV &&. DVVD\V ZHUH
performed at the indicated time points after infection. The 
results were expressed as survival rate of untreated control. 
7KHUHVXOWVVKRZHGWKDW$GK7(57S,/LQKLELWHGWKH
growth of HepG2 cells (Figure 4A), but not of MRC-5 
cells (Figure 4B), suggesting that the hTETR promoter, 
DVZHOODV,/SOD\DSRVLWLYHUROHRQO\LQWXPRUFHOOV
,WKDVEHHQUHSRUWHGWKDWDGHQRYLUXVLQFRPELQDWLRQ
with 5-Fu or other chemotherapeutic reagents can 
HI¿FLHQWO\ HOLPLQDWH FDQFHU FHOOV DQG WXPRUV LQ YLYR
>±@ :H IXUWKHU HYDOXDWHG WKH LQKLELWLRQ HI¿FDF\
RI $GK7(57S,/ LQ FRPELQDWLRQ ZLWK D ORZGRVH
of 5-Fu on HepG2 growth. Two concentrations of 5-Fu 
ZHUH XVHG LQ FRPELQDWLRQ ZLWK WKH DGHQRYLUXV  ȝJ
PO DQGȝJPO FRUUHVSRQGLQJ WR DQ LQKLELWLRQ UDWHRI
11.30±1.27% and 21.25±1.34%, respectively (Figure 4C). 
7KHWXPRUFHOONLOOLQJDELOLW\ZDVVLJQL¿FDQWO\LQFUHDVHG
ZKHQ +HS* ZHUH WUHDWHG ZLWK $GK7(57S,/ LQ
combination with 5-Fu, compared with Ad-hTERTp-
,/RU)XWUHDWPHQWDORQH)LJXUH'6XUSULVLQJO\
AdTrack combined with 5-Fu also caused more tumor 
cells death than 5-Fu treatment alone, as discussed in the 
next paragraph. To determine whether the adenovirus 
and 5-Fu interacted synergistically, the combination 
LQGH[ &, RI FRPELQDWLRQ WUHDWPHQW ZDV FDOFXODWHG
Strong synergistic cell killing was observed for 5-Fu in 
FRPELQDWLRQZLWK$GK7(57S,/DQGORZV\QHUJLVP
)LJXUH6SHFL¿FWXPRUVXSSUHVVLQJHIIHFWVRI$GK7(57S,/DQGORZGRVHRI)XFRXOGHQKDQFHJURZWKLQKLELWLRQ
RI+HS*FHOOV $7KHFHOOYLDELOLW\RI+HS*FHOOVZDVPHDVXUHGHYHU\KRXUVDIWHULQIHFWLRQZLWKGLIIHUHQWDGHQRYLUXVHVDW02,
100 by CCK8 assays. The results were expressed as survival rate of untreated control.** P<0.01. % The cell viability of MRC-5 cells was 
PHDVXUHGHYHU\KRXUVDIWHULQIHFWLRQZLWKGLIIHUHQWDGHQRYLUXVHVDW02,E\&&.DVVD\V& The inhibitory rate curve of HepG2 
cells treated with 5-Fu gradient concentrations was analyzed. '7KHVXUYLYDOUDWHVRI+HS*FHOOVLQIHFWHGE\DGHQRYLUXVHVDW02,LQ
the presence or absence of low doses of 5-Fu were tested by CCK8 assay and expressed as mean ± SD. *P<0.05, ** P<0.01 compared with 
)XWUHDWPHQWJURXSPPFRPSDUHGZLWK$GK7(57S,/WUHDWPHQWJURXS( Apoptosis ratios were detected when 5-Fu 
LQFRPELQDWLRQZLWK$GK7(57S,/RU$G7UDFNDQGH[SUHVVHGDVPHDQ6'P<0.05, ** PFRPSDUHGZLWK)XWUHDWPHQWJURXS
PPFRPSDUHGZLWK$GK7(57S,/WUHDWPHQWJURXS):HVWHUQEORWVKRZHGSURWHLQVLQYROYHGLQDSRSWRVLVSDWKZD\
ZKHQ)XLQFRPELQDWLRQZLWK$GK7(57S,/RU$G7UDFN$OOWKHGDWDUHSUHVHQWWKHDYHUDJHVRIWKUHHLQGHSHQGHQWH[SHULPHQWV
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with AdTrack (Table 1). A similar synergistic effect was 
discovered in the apoptosis assays when 5-Fu was used in 
FRPELQDWLRQZLWK$GK7(57S,/RU$G7UDFN)LJXUH
(:HVWHUQEORWWLQJDVVD\VVKRZHGWKDW,/H[SUHVVLRQ
OHYHOV ZHUH JUHDWO\ LQFUHDVHG LQ WKH$GK7(57S,/
group, and promoted p38MAPK phosphorylation (Figure 
4F), correlating cell killing with the activation of the 
p38MAPK pathway. Furthermore, Bax protein expression 
levels increased, while Bcl-2 protein expression decreased, 
and other apoptosis-related proteins such as PARP, 
caspase-3 and 9, were cleaved and activated. All of these 
FKDQJHVZHUHVLJQL¿FDQWO\PRUHUREXVWZKHQ$GK7(57S
,/DQG)XZHUHFRPELQHG)LJXUH)
&$5DQGĮȞȕ3H[SUHVVLRQOHYHOVHVVHQWLDOIRU
YLUXVLQWHUQDOL]DWLRQZHUHLQFUHDVHGLQUHVSRQVH
WRORZGRVHVRI)XFDXVLQJH[FHVVLYHDGHQRYLUDO
XSWDNH
:H REVHUYHG WKDW DGHQRYLUDO LQIHFWLRQ HI¿FLHQF\
was improved when combined with low doses of 5-Fu 
(Figure 5A). Flow cytometry analysis also showed that 
WKHÀXRUHVFHQFH LQWHQVLW\RI WKHFRPELQDWLRQ WUHDWPHQW
group was higher than the adenoviral treatment alone 
(Figure 5B). To test whether the synergistic effect was due 
to increased susceptibility to adenoviral infection in the 
presence of 5-Fu, HepG2 cells were infected with AdTrack 
7DEOH&RPELQDWLRQLQGH[&,RIDGHQRYLUXVFRPELQHGZLWK)X
)8ȝJPO $G7UDFN02, $GK7(57S,/02,
1 0.85 0.75
2 0.73 0.64
)LJXUH&$5DQGĮȞȕH[SUHVVLRQOHYHOVHVVHQWLDOIRUYLUXVLQWHUQDOL]DWLRQZHUHLQFUHDVHGLQUHVSRQVHWRORZGRVHVRI
)XFDXVLQJH[FHVVLYHDGHQRYLUDOXSWDNH $5HSUHVHQWDWLYHLPDJHVVKRZHGWKHWUDQVIHFWLRQRI+HS*ZLWK02,$G7UDFNLQ
WKHSUHVHQFHRUDEVHQFHRIORZGRVHRI)XȝJPOKRXUVDIWHULQIHFWLRQ+HS*FHOOVZHUHREVHUYHGXQGHUÀXRUHVFHQW¿HOGDERYH
SDQHODQGEULJKW¿HOGEHORZSDQHO%+LVWRJUDPRYHUOD\VRIÀRZF\WRPHWU\UHYHDOHGWKDWWKHÀXRUHVFHQFHLQWHQVLW\RIHDFKJURXSLQWKH
)LJXUH$7KHUHGSHDNUHSUHVHQWHGJURXSRIDGHQRYLUXVLQFRPELQHGZLWK)XWKHEOXHSHDNUHSUHVHQWHGJURXSRIDGHQRYLUXVDORQHWKH
green peak represented group of negative control. &7KHLQIHFWLRQHI¿FLHQFLHVRIDGHQRYLUXVIRU+HS*DWGLIIHUHQW02,VZHUHLPSURYHG
by low doses of 5-Fu. ' The expression level of CAR on the surface of HepG2 cells was detected every 24 hours after low doses of 5-Fu 
treatment. (7KHH[SUHVVLRQOHYHORIĮȞȕ3 on the surface of HepG2 cells was detected every 24 hours after low doses of 5-Fu treatment. 
)7KHH[SUHVVLRQOHYHORIĮȞȕ5 on the surface of HepG2 cells was detected every 24 hours after low doses of 5-Fu treatment. *P<0.05, ** 
P<0.01 compared with group of without 5-Fu treatment.
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DWGLIIHUHQW02,VLQWKHSUHVHQFHRUDEVHQFHRIORZGRVHV
of 5-Fu. Dose-dependent increases in viral uptake from 
WR02,ZHUHREVHUYHGDQGVLJQL¿FDQWLQFUHDVHV
LQYLUDOXSWDNHZHUHGHWHFWHGDWDOO02,VLQWKHSUHVHQFH
of low doses of 5-Fu (Figure 5C). Next, we investigated 
whether the expression levels of the viral attachment 
receptor CAR and the major internalization receptors 
ĮȞȕ3DQGĮȞȕ5integrins were increased in response to 5-Fu 
WUHDWPHQWFDXVLQJ WKHKLJKHUYLUDOXSWDNH ,QXQWUHDWHG
HepG2 cells, the baseline CAR membrane levels reduced 
gradually with the increase of time in culture, and they 
were 17.60±4.38%, 13.95±4.45%, 6.53±3.31% at 24, 48 
and 72 hours, respectively. While in the presence of 5-Fu, 
WKH FHOO VXUIDFH H[SUHVVLRQ OHYHOV RI&$5VLJQL¿FDQWO\
LQFUHDVHGLQ+HS*FHOOV)LJXUH')RULQWHJULQĮȞȕ3, 
baseline expression was low (<10%), and it slightly 
increased after 5-Fu treatment (Figure 5E). For integrin 
ĮȞȕ5, baseline expression was as high as 100%, and 5-Fu 
treatment did not affect its expression levels (Figure 
5F). All these observations might explain the excessive 
adenoviral uptake and the enhanced cytotoxicity when the 
adenovirus was combined with low doses of 5-Fu.
$QWLWXPRUSRWHQWLDORI$GK7(57S,/ORDGHG
06&/HQWL5($LQFRPELQDWLRQZLWK)X
DJDLQVW+HS*[HQRJUDIWWXPRUV
We further investigated the antitumor potential of 
DGHQRYLUXVORDGHG06&/HQWL5($LQFRPELQDWLRQZLWK
)X LQ %$/%& QXGHPLFH WUDQVSODQWHG ZLWK +HS*
human hepatocellular carcinoma cells. Compared with 
the mice in the control group (untreated), the mice treated 
ZLWK06&/HQWL5($$GK7(57S,/ZLWKRUZLWKRXW
5-Fu all exhibited evident tumor regression, especially in 
WKH06&/HQWL5($$GK7(57S,/SOXV)XJURXS
the tumor inhibition rate of which reached 71.21% 21 
GD\VDIWHUWUHDWPHQW)LJXUH$$QLPDOVZHUHVDFUL¿FHG
when tumors had grown to approximately 2000 mm3 in 
VL]H7XPRUVZHUHGLVVHFWHGDQG¿[HGLQIRUPDOLQIRU
SDUDI¿QHPEHGGLQJ
,PPXQRKLVWRFKHPLVWU\ VKRZHG PDUNHG ,/
expression (red) around the tumor cells (green) in the 
JURXSWUHDWHGZLWK06&/HQWL5($$GK7(57S,/
)LJXUH(,QFRQWUDVWZHFRXOGREVHUYH*)3H[SUHVVLQJ
FHOOVQHJDWLYHIRU,/H[SUHVVLRQDPRQJWXPRUWLVVXHVLQ
WKHJURXSRI06&/HQWL5$GK7(57S,/)LJXUH&
,QWKH06&/HQWL5($$G7UDFNJURXS*)3H[SUHVVLQJ
WXPRUFHOOV ODFNLQJ ,/H[SUHVVLRQZHUHREVHUYHGDV
expected (Figure 6D). Previous research has shown that 
a portion of transplanted HUMSCs are entrapped when 
injected intravenously [28, 31]. To investigate the fate of 
HUMSCs trapped by pulmonary capillaries in the lung, 
ZHDOVRGHWHFWHGWKHH[SUHVVLRQRI,/DQG*)3LQOXQJ
WLVVXHVWUHDWHGZLWK06&/HQWL5($$GK7(57S,/
1HLWKHU,/QRU*)3H[SUHVVLQJFHOOVZHUHGHWHFWHGLQ
the lung (Figure 6F). The trapped HUMSCs had probably 
died rapidly due to the unsuitable environment, and 
they had released sporadic adenoviral particles in lung, 
LQGLFDWLQJ WKH WLVVXHVSHFL¿FLW\ RI WKLV GXDO WDUJHWHG
system.
)XUWKHU781(/VWDLQLQJZDVSHUIRUPHGWRHYDOXDWH
the apoptosis-inducing ability of this targeted system 
LQ YLYR 7XPRUV WUHDWHG ZLWK 06&/HQWL5($$G
K7(57S,/ZLWKRUZLWKRXW)XSUHVHQWHGVLJQL¿FDQWO\
apoptosis, which was limited to the tumor mass (Figure 
./7KH DSRSWRWLF DFWLYLW\ GHWHFWHG LQ RWKHU WUHDWHG
JURXSVZDVPXFKORZHUWKDQLQWKH06&/HQWL5($$G
K7(57S,/SOXV)XJURXS)LJXUH*±-LQGLFDWLQJ
WKDW06&/HQWL5($$GK7(57S,/DQG)XZHUH
synergistically induced tumor cell death in vivo.
DISCUSSION
We successfully established a new targeted treatment 
system based on HUMSCs, which were engineered to 
GHOLYHUD UHSOLFDWLRQGH¿FLHQW DGHQRYLUDOYHFWRU DQG WR
enable its replication and assembling into new viruses to 
tumor sites in a mouse model of hepatocellular carcinoma. 
Our results showed that engineered HUMSCs have the 
ability to incorporate into tumors and release cancer-killing 
DGHQRYLUDO SDUWLFOHV 06&/HQWL5($ $GK7(57S
,/WUHDWPHQWH[KLELWHGVLJQL¿FDQWDQWLWXPRUHIIHFWVRQ
the transplanted hepatocarcinoma, which were mediated 
E\$GK7(57S,/$GGLWLRQDOO\WKLVWXPRUVXSSUHVVLQJ
effect was greatly strengthened when combined with low 
doses of 5-Fu, due to the increased expression of CAR 
DQGĮȞȕ3 on tumor cells in response to low doses of 5-Fu. 
Previously, a similar targeted therapeutic strategy has 
been reported. Ando and his colleagues adapted a suicide 
system based on an inducible caspase-9 (iC9) protein 
WKDW LV DFWLYDWHG XVLQJ D VSHFL¿F FKHPLFDO LQGXFHU RI
GLPHUL]DWLRQ&,'IRUDGHQRYLUDOEDVHGGHOLYHU\WROXQJ
WXPRUVWKURXJK06&V>@7KHLU¿QGLQJVVXJJHVWHGWKDW
WKLVDSSURDFKFRXOGEHXVHGWRNLOO16&/&LQYLWURDQG
in an orthotopic mouse xenograft model of lung cancer. 
Compared with this study, our results not only showed 
the effectively anti-tumor activity of this strategy but also 
provided more evidence of adenoviral replication in vitro 
and in vivo (Figures 2 and 3).
The tumor-migrating tropism of MSCs has been 
acknowledged in recent years. Due to its applications to 
tumor treatment, increasingly frequent investigations have 
been performed on the kinetic distribution of systemically 
administered MSCs in vivo and on the time required 
for MSCs to the tumor site [11, 33, 34]. Our laboratory 
previously demonstrated by luciferase bioluminescence 
in vivo that MSCs migrate and selectively accumulated 
at the tumor site at 24 h after intravenous injection [34]. 
Further, Xi Xia [33] investigated the distribution pattern 
RI 06&V LQ D VSHFL¿F WLPH SHULRG UDQJLQJ IURP 
h to 72 h after injection, and found that the number of 
06&V LQ WKH WXPRU LQFUHDVHG RYHU WLPH ,Q WKLV VWXG\
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)LJXUH7XPRUVXSSUHVVLQJHIIHFWVRI$GK7(57S,/ORDGHG06&/HQWL5($LQFRPELQDWLRQZLWK)XDJDLQVW
+HS*[HQRJUDIWWXPRUV $ The tumor volumes of different groups were measured every 3 days after treatment. Points indicate the 
mean values (n EDUVLQGLFDWH6'P<0.05, ** P<0.01 compared with PBS group. %) The target protein expression was detected 
LQ GLIIHUHQW JURXSVE\ FRQIRFDOPLFURVFRS\7KH UHGÀXRUHVFHQFH UHSUHVHQWHG ,/SURWHLQV WKHJUHHQÀXRUHVFHQFH UHSUHVHQWHG WKH
FHOOVLQIHFWHGE\DGHQRYLUXV7KHEOXHÀXRUHVFHQFHVKRZHGWKHQXFOHL%3%6&06&/HQWL5$GK7(57S,/'06&/HQWL5
($$G7UDFN (06&/HQWL5($$GK7(57S,/ )7KH OXQJ WLVVXH RI WKH JURXS RI06&/HQWL5($$GK7(57S,/ 
*/781(/VWDLQLQJUHYHDOHGDSRSWRVLVLQWKHWXPRUVRIGLIIHUHQWWUHDWPHQWJURXSV&\ODEHOHG781(/SRVLWLYHFHOOVRQWKHVHFWLRQVZHUH
GHWHFWHGE\FRQIRFDOPLFURVFRS\*3%6+)X,06&/HQWL5$GK7(57S,/)X-06&/HQWL5($$G7UDFN)X 
.06&/HQWL5($$GK7(57S,//06&/HQWL5($$GK7(57S,/)X
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the therapeutic adenoviruses were delivered to tumor 
VLWHVDQGDPSOL¿HGE\+806&VVHTXHQWLDOO\LQIHFWHGE\
$GK7(57S,/ DQG /HQWL5($:H IRXQG WKDW WKH
adenovirus could extensively amplify in HUMSCs 36 
KDIWHU WKH WUDQVGXFWLRQRI/HQWL5($LQYLWUR+HQFH
the lentiviral expression of E1A, which is necessary 
IRUDGHQRYLUDODPSOL¿FDWLRQUHTXLUHVDWOHDVWK7KH
increased expression of E1A was accompanied by massive 
DGHQRYLUDODPSOL¿FDWLRQDQGUHDFKHGSHDNOHYHOVDW
h. Furthermore, in vivo experiments demonstrated that 
it took no longer than 48 h for most of the virus-loaded 
+806&VWRUHDFKWKHWXPRUVLWHV7KHVH¿QGLQJVVXJJHVW
that, taking advantage of the delay of lentiviral gene 
H[SUHVVLRQDVXI¿FLHQWQXPEHURI+806&VFRXOGPLJUDWH
to tumor sites before being lysed.
Recently, MSCs have been demonstrated to deliver 
conditionally replicative adenovirus (CRAd) to various 
malignant tumors. These viruses are able to destroy tumor 
cells by replication and consequent oncolysis, which 
enables the newly produced virus to be released to the 
surrounding tumor tissues to prevent tumor growth [6, 
11, 33, 35]]. However, a considerable number of CRAd-
loaded MSCs were also found in the lung, liver, and 
spleen, with the exception of the tumor site after systemic 
administration [33]. These ectopic CRAd-loaded MSCs 
would produce virus to injury normal tissues as well, 
GXHWRWKHLUODFNRIDEVROXWHVSHFL¿FLW\ZKLFKOLPLWVWKH
HIIHFWLYH XVH RI &5$G LQ FOLQLFDO DSSOLFDWLRQV ,Q RXU
study, we used E1A-engineered HUMSCs to deliver a 
UHSOLFDWLRQGH¿FLHQWDGHQRYLUXVZKLFKFDQUHSOLFDWHDQG
assemble into new viruses to tumor sites. The replication-
GH¿FLHQW DGHQRYLUXV UHSOLFDWHG RQO\ LQ +806&V EXW
not tumor cells or other normal cells because of the 
complementary expression of E1A in HUMSCs.
Combining adenoviral constructs with 
chemotherapeutics has represented an appealing strategy to 
increase their potency [36]. Several studies have presented 
combinatory cytotoxic effects in esophageal carcinoma by 
Ad-delE1B55 in combination with 5-Fu [37], in pancreatic 
adenocarcinoma model by Ad-dl922-947 in combination 
with 5-Fu or gemcitabine [29], and in patients with 
recurrent head and neck cancer by intratumoral ONYX-015 
in combination with cisplatin or 5-Fu [30]. The reasonable 
explanation for combinatory cytotoxic effects on tumors 
was that chemotherapeutic agents increased adenoviral 
LQIHFWLYLW\ GHSHQGHQW RQ &$5 ĮȞȕ3 DQG ĮȞȕ5 [29] or 
associated with morphological changes in lipid membranes 
>@,QWKLVVWXG\ZHLQYHVWLJDWHGWKHHIIHFWVRI)XDVLW
is frequently used for hepatocellular carcinoma treatment. 
Synergistic tumor cell inhibition was observed for 5-Fu in 
FRPELQDWLRQZLWK$GK7(57S,/DVZHOODV$G7UDFNLQ
vitro and in vivo. Two explanations might account for the 
V\QHUJ\¿UVWWKHH[SUHVVLRQOHYHORI&$5ZDVLQFUHDVHG
in response to the 5-Fu treatment, causing the higher 
YLUDOXSWDNHVHFRQGRYHUH[SUHVVHG,/FRXOGHQKDQFH
sensitivity of cancer cells to 5-Fu [39].
,Q FRQFOXVLRQ WKLV ZRUN LQYHVWLJDWHV D SURPLVLQJ
targeted therapeutic strategy using E1A-engineered 
+806&V WR GHOLYHU DQG SURGXFH UHSOLFDWLRQGH¿FLHQW
adenovirus against hepatocarcinoma to tumor sites. The 
therapeutic strategy provides a new, effective and safe 
DGPLQLVWUDWLRQ URXWH IRU UHSOLFDWLRQGH¿FLHQW DGHQRYLUXV
WR UHVROYH WKH SUREOHP RI LQHI¿FLHQW YLUXV GHOLYHU\ WR
inaccessible and/or metastatic tumor sites. Meanwhile, 
it also solves the potential safety hazard of HUMSCs. 
However, this therapeutic system retains some problems 
that will need to be improved in the future. For example, 
the expression of E1A can be controlled by an inducible 
promoter, which would ensure more HUMSCs migrate to 
tumor sites before lysis, enhancing the tumor-suppressing 
effect. Additional studies are warranted to demonstrate 
the superiority of this therapeutic strategy in the tumor 
metastasis models, which would make it highly appealing 
for the treatment of tumor patients with metastatic diseases.
0$7(5,$/6$1'0(7+2'6
&HOOFXOWXUH
The human hepatocellular carcinoma cell line 
+HS* DQG WKH KXPDQ HPEU\RQLF OXQJ ¿EUREODVW FHOO
line MRC-5 were obtained from the Cell Resource 
Center, Peking Union Medical College (which is the 
KHDGTXDUWHU RI WKH1DWLRQDO ,QIUDVWUXFWXUHRI&HOO/LQH
5HVRXUFH167,RQ0D\WK&HOOVZHUHWHVWHG
for the absence of mycoplasma contamination by PCR 
DQG FXOWXUH &HOO VSHFLHV ZDV FRQ¿UPHG E\ 3&5 7KH
identity of the cell lines was authenticated with STR 
SUR¿OLQJ)%,&2',6$OOWKHUHVXOWVFDQEHYLHZHGRQ
the website (http://cellresource.cn). Cells were maintained 
LQ '0(0 VXSSOHPHQWHG ZLWK  )%6 DQG Į0(0
supplemented with 1×MEM Non-Essential Amino Acids 
and 10% FBS, respectively. The human embryonic renal 
FHOOOLQH$,QVWLWXWHRI+HPDWRORJ\	%ORRG'LVHDVHV
+RVSLWDO&KLQHVH$FDGHP\RI0HGLFDO6FLHQFHV	3HNLQJ
Union Medical College, PUMC), and human embryonic 
kidney cell derived 293T cell line (kindly provided by 
Professor Cheng Tao, PUMC) were maintained in DMEM 
supplemented with 10% FBS. Cells were cultured in a cell 
incubator containing 5% CO2 at 37°C.
+806&VSUHSDUDWLRQ
HUMSCs were isolated from human umbilical 
cord Wharton’s jelly (WJ) as previously described [27]. 
HUMSCs were seeded at a density of 8×103 cells/cm2 in 
')VXSSOHPHQWHGZLWKPPROO/JOXWDPLQHDQG
)%6:KHQFHOOVUHDFKHGaFRQÀXHQFHWKH\ZHUH
detached using a 0.125% trypsin/1 mM EDTA solution, 
and re-seeded using the same growth media for subsequent 
passages. Cells at passage number 3-5 were used for the 
following experiments.
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5HFRPELQDQWDGHQRYLUXVUHOHDVHIURP+806&
/HQWL5($LQYLWUR
HUMSCs were seeded in 6-well plates at a density 
of 1×105 cells/well and incubated overnight at 37°C. 
On the next day, the HUMSCs were infected with Ad-
K7(57S,/DWPXOWLSOLFLW\RILQIHFWLRQ02,IRU
6 hours. Then, the culture medium was replaced with 
IUHVKPHGLXPFRQWDLQLQJOHQWLYLUDOVXSHUQDWDQWV/HQWL5
RU/HQWL5($DW02,ZLWKȝJPOSRO\EUHQH6LJPD
Santa Clara, CA). Twelve hours later, the medium was 
replaced. HUMSCs and supernatants were harvested after 
the indicated periods of lentiviral infection, and used for 
DGHQRYLUDO'1$SUHSDUDWLRQXVLQJ WKH+LJK3XUH9LUDO
Nucleic Acid Extraction Kit (Roche, Basel, Switzerland). 
4XDQWLWDWLYH UHDOWLPH 3&5 ZDV SHUIRUPHG XVLQJ$%,
35,60  UHDO WLPH 3&5 V\VWHP 6<%5 JUHHQ
technology was used to detect a 286-bp-long amplicon 
(nucleotides 21049-21334) within the conserved region 
of the Ad5 hexon gene. The primers were designed as 
IROORZV ƍ**7**&&$77$&&777*$&7&77&ƍ
DQGƍ&&$&&7*77**7$*7&&77*7$777$*7$7&
$7&ƍ3&5F\FOHVZHUHSURJUDPPHGDFFRUGLQJWRWKH
manufacturer’s instructions for SYBR Premix Ex Taq 
reagent (Takara, Dalian, China). The standard curve for 
DGHQRYLUXVTXDQWL¿FDWLRQZDVJHQHUDWHGE\VHULDOGLOXWLRQV
of pAdTrack plasmid. The experiments were repeated for 
three times.
0LJUDWLRQDVVD\RIYLUXVORDGHG+806&VLQ
YLWURDQGLQYLYR
The migration of virus-loaded HUMSCs was 
GHWHUPLQHGXVLQJȝPSRUHPHPEUDQHLQVHUWVZLWKPP
diameter (BD Falcon, New York, USA). 12 hours after co-
infection, 1×105 HUMSCs were plated in the top chamber 
LQȝORIVHUXPIUHHPHGLXP7KHSUHYLRXVGD\+HS*
cells were seeded at a density of 5×104 cells/well in the 
lower chamber in fresh medium containing 2% FBS. After 
20 h incubation at 37°C, cells that had not migrated from 
the upper side of the membrane were scraped off with 
a cotton swab, and membranes were stained with 0.1% 
crystal violet at 37°C for 45 min. Cells that had migrated 
WRWKHORZHUVLGHRIWKHPHPEUDQHZHUHTXDQWL¿HG7KH
QXPEHURIFHOOVZDVGHWHUPLQHGLQ¿YHUDQGRPO\VHOHFWHG
KLJKSRZHUîPLFURVFRSH¿HOGV([SHULPHQWVZHUH
performed in triplicate.
For the in vivo HUMSC migration assays, we 
GHYHORSHG DQ DGHQRYLUDO YHFWRU FRQWDLQLQJ D ¿UHÀ\
OXFLIHUDVH UHSRUWHU JHQH S$G/XF 6HYHQ GD\V DIWHU
HepG2 cells inoculation into the mouse right armpits, 
when the solid tumors reached 100-200 mm3 in size, 
1×106+806&VZHUHLQIHFWHGE\$G/XFDW02,
IROORZHG E\ /HQWL5($ LQIHFWLRQ IRU  KRXUV DQG
injected into mice via the tail vein to detect cell migration. 
%LROXPLQHVFHQFH LPDJLQJ ZDV SHUIRUPHG XVLQJ ,9,6
;HQRJHQV\VWHP&DOLSHU/LIHVFLHQFHV86$DWWKH
indicated times, as previously described [28].
*URZWKLQKLELWLRQRIKHSDWRFHOOXODUFDUFLQRPD
+HS*[HQRJUDIWVLQYLYR
All animal procedures were approved by the 
Committee on the use and care of animals, Chinese 
Academy of Medical Science. 5-6-weeks-old female 
%$/%F QXGH PLFH ZHUH LQRFXODWHG VXEFXWDQHRXVO\
with 5×106 HepG2 cells into right armpits. 7 days after 
tumor inoculation, when solid tumors reached 100-200 
mm3 in size, mice were randomized into 9 groups (7 
PLFH IRU HDFK JURXS DV IROORZV  3%6 FRQWURO 
+806&)X06&/HQWL5$GK7(57S,/
06&/HQWL5$GK7(57S,/DQG)X06&
/HQWL5($$G7UDFN  06&/HQWL5($$G7UDFN
DQG )X  06&/HQWL5($$GK7(57S,/
 06&/HQWL5($$GK7(57S,/ DQG )X
The HUMSCs were co-infected as described above and 
injected intravenously with 1×106 cells/mouse. 5-Fu was 
i.p. injected at a dose of 10 mg/kg for 5 continuous days 
starting 3 days after HUMSCs injection. Growing tumors 
were measured every three days using a vernier caliper in 
two perpendicular dimensions. The tumor volumes were 
FDOFXODWHG XVLQJ WKH IROORZLQJ IRUPXOD 9 /î:
ZKHUH / UHSUHVHQWV WKH ORQJHVW D[LV RI WKH WXPRUV LQ
PP DQG: UHSUHVHQWV WKH D[LV SHUSHQGLFXODU WR/ LQ
PP0LFHZHUHVDFUL¿FHGE\FHUYLFDOGLVORFDWLRQXQGHU
anesthesia when the tumors reached 2000 mm3 in size, and 
tumor tissues were harvested and weighed.
,PPXQRKLVWRFKHPLFDODQDO\VLVIRUWKHH[SUHVVLRQ
RI,/
7XPRU WLVVXHV ZHUH ¿[HG LQ  IRUPDOLQ DQG
HPEHGGHG LQ SDUDI¿Q EORFNV  ȝP VHFWLRQV ZHUH
REWDLQHG IRU +	( VWDLQLQJ DQG VXEVHTXHQW DQDO\VLV
7KHH[SUHVVLRQRI,/LQWKHWXPRUVWUHDWHGE\06&
/HQWL5($ $GK7(57S,/ ZDV GHWHFWHG E\
LPPXQRKLVWRFKHPLVWU\ ,Q EULHI WKH SDUDI¿Q VHFWLRQV
ZHUHGHSDUDI¿QL]HG LQ[\OHQH DQG UHK\GUDWHG WKURXJK
a series of graded-ethanol and PBS solutions. Antigen 
retrieval was performed by heated in a hot bath. Sections 
were then treated with goat serum for 30 min at room 
temperature followed by incubation with rabbit anti-
,/PRQRFORQDODQWLERG\$EFDP&DPEULGJH8.
and mouse anti-GFP monoclonal antibody (Abbkine, 
CA) at 4°C overnight. On the following day, sections 
were incubated with secondary polyclonal donkey 
DQWLUDEELW '\/LJKW FRQMXJDWHG DQWLERG\ DQG
VHFRQGDU\SRO\FORQDOUDEELWDQWLPRXVH),7&FRQMXJDWHG
antibody for 30 min. 4, 6-diamidino-2-phenylindole 
'$3,6LJPD6DQWD&ODUD&$ZDVXVHGIRUQXFOHDU
staining. The stained sections were imaged by confocal 
PLFURVFRS\/HLFD7&663*HUPDQ\
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,QVLWXDQDO\VLVRIDSRSWRWLFFHOOV
Apoptotic cells in the tumors were detected by 
terminal deoxynucleotidyl transferase dUTP nucleotide 
QLFNHQGODEHOLQJ781(/%ULHÀ\DFRPPHUFLDORQH
VWHS781(/DSRSWRVLVDVVD\NLW %H\RWLPH,QVWLWXWHRI
Biotechnology, Shanghai, China) was used according 
WRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV&\ODEHOHG781(/
positive cells on the sections were detected by confocal 
microscopy.
6WDWLVWLFDODQDO\VLV
Data were analyzed using an independent sample 
t-tests and were represented as the mean ± SD. P<0.05 
ZDVFRQVLGHUHGWREHVWDWLVWLFDOO\VLJQL¿FDQWDQGP<0.01 
ZDVFRQVLGHUHGWREHKLJKO\VWDWLVWLFDOO\VLJQL¿FDQW
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